CERo Therapeutics Holdings (CERo Therapeutics Holdings) Net Income From Continuing Operations : $-11.83 Mil (TTM As of Dec. 2022)

View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. CERo Therapeutics Holdings's net income from continuing operations for the six months ended in Dec. 2022 was $-11.83 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2022 was $-11.83 Mil.

CERo Therapeutics Holdings Net Income From Continuing Operations Historical Data

The historical data trend for CERo Therapeutics Holdings's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Net Income From Continuing Operations Chart

CERo Therapeutics Holdings Annual Data

Trend

Dec21

Dec22

Net Income From Continuing Operations

-10.63

-11.83

CERo Therapeutics Holdings Semi-Annual Data
	Dec21	Dec22
Net Income From Continuing Operations	-10.63	-11.83

CERo Therapeutics Holdings Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2022 was $-11.83 Mil.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080

Website

https://www.cero.bio

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines

From GuruFocus

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of Its Clinical Candidate CER-1236 to Treat AML Patients

By Business Wire • 03-07-2024